Pheochromocytoma

References

• Omura M , SaitoJ, YamaguchiKet al. Prospective study on the prevalence of secondary hypertension among hypertensive patients visiting a general outpatient clinic in Japan. Hypertens. Res.27(3), 193–202 (2004).
   PubMed Web of Science ®Google Scholar
• Tischler AS . Paraganglia. In: Histology for Pathologists (4th Edition), MillsSE ( Ed.). Lippincott, Williams & Wilkins, PA, USA, 1277–1299 (2012).
   Google Scholar
• Plouin PF , DuclosJM, SoppelsaFet al. Factors associated with perioperative morbidity and mortality in patients with pheochromocytoma: analysis of 165 operations at a single center. J. Clin. Endocrinol. Metab.86(4), 1480–1486 (2001).
   PubMed Web of Science ®Google Scholar
• Stolk RF , BakxC, MulderJet al. Is the excess cardiovascular morbidity in pheochromocytoma related to blood pressure or to catecholamines? J. Clin. Endocrinol. Metab. 98(3), 1100–1106 (2013).
   PubMed Web of Science ®Google Scholar
• Prejbisz A , LendersJW, EisenhoferGet al. Cardiovascular manifestations of phaeochromocytoma. J. Hypertens.29(11), 2049–2060 (2011).
   PubMed Web of Science ®Google Scholar
• Ayala-Ramirez M , FengL, JohnsonMMet al. Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators. J. Clin. Endocrinol. Metab.96(3), 717–725 (2011).
   PubMed Web of Science ®Google Scholar
• Amar L , ServaisA, Gimenez-RoqueploAPet al. Year of diagnosis, features at presentation, and risk of recurrence in patients with pheochromocytoma or secreting paraganglioma. J. Clin. Endocrinol. Metab.90(4), 2110–2116 (2005).
   PubMed Web of Science ®Google Scholar
• Lo CY , LamKY, WatMSet al. Adrenal pheochromocytoma remains a frequently overlooked diagnosis. Am. J. Surg.179(3), 212–215 (2000).
   PubMed Web of Science ®Google Scholar
• Waguespack SG , RichT, GrubbsEet al. A current review of the etiology, diagnosis, and treatment of pediatric pheochromocytoma and paraganglioma. J. Clin. Endocrinol. Metab.95(5), 2023–2037 (2010).
   PubMed Web of Science ®Google Scholar
• Lenders JW , EisenhoferG, MannelliMet al. Phaeochromocytoma. Lancet366(9486), 665–675 (2005).
   PubMed Web of Science ®Google Scholar
• Mansmann G , LauJ, BalkEet al. The clinically inapparent adrenal mass: update in diagnosis and management. Endocr. Rev.25(2), 309–340 (2004).
   PubMed Web of Science ®Google Scholar
• Manger WM . The protean manifestations of pheochromocytoma. Horm. Metab. Res.41(9), 658–663 (2009).
   PubMed Web of Science ®Google Scholar
• LaBatide-Alanore A , ChatellierG, PlouinPF. Diabetes as a marker of pheochromocytoma in hypertensive patients. J. Hypertens.21(9), 1703–1707 (2003).
   PubMed Web of Science ®Google Scholar
• Manger W , GiffordR. Clinical and Experimental Pheochromocytoma.Blackwell Science, MA, USA (1996).
   Google Scholar
• Werbel SS , OberKP. Pheochromocytoma. Update on diagnosis, localization, and management. Med. Clin. North Am.79(1), 131–153 (1995).
   PubMed Web of Science ®Google Scholar
• Kebebew E , DuhQY. Benign and malignant pheochromocytoma: diagnosis, treatment, and follow-up. Surg. Oncol. Clin. N. Am.7(4), 765–789 (1998).
   PubMedGoogle Scholar
• Eisenhofer G , RiversG, RosasALet al. Adverse drug reactions in patients with phaeochromocytoma: incidence, prevention and management. Drug Saf.30(11), 1031–1062 (2007).
   PubMed Web of Science ®Google Scholar
• Bravo EL , TagleR. Pheochromocytoma: state-of-the-art and future prospects. Endocr. Rev.24(4), 539–553 (2003).
   PubMed Web of Science ®Google Scholar
• Zelinka T , StrauchB, PetrakOet al. Increased blood pressure variability in pheochromocytoma compared to essential hypertension patients. J. Hypertens.23(11), 2033–2039 (2005).
   PubMed Web of Science ®Google Scholar
• Bergland BE . Pheochromocytoma presenting as shock. Am. J. Emerg. Med.7(1), 44–48 (1989).
   PubMed Web of Science ®Google Scholar
• Brouwers FM , LendersJW, EisenhoferGet al. Pheochromocytoma as an endocrine emergency. Rev. Endocr. Metab. Disord.4(2), 121–128 (2003).
   PubMed Web of Science ®Google Scholar
• Goldstein DS . Stress, Catecholamines, and Cardiovascular Disease.Oxford University Press, NY, USA, 289–328 (1995).
   Google Scholar
• Lenders JW , PacakK, WaltherMMet al. Biochemical diagnosis of pheochromocytoma: which test is best? JAMA 287(11), 1427–1434 (2002).
   PubMed Web of Science ®Google Scholar
• Hickman PE , LeongM, ChangJet al. Plasma free metanephrines are superior to urine and plasma catecholamines and urine catecholamine metabolites for the investigation of phaeochromocytoma. Pathology41(2), 173–177 (2009).
   PubMed Web of Science ®Google Scholar
• Peaston RT , GrahamKS, ChambersEet al. Performance of plasma free metanephrines measured by liquid chromatography-tandem mass spectrometry in the diagnosis of pheochromocytoma. Clin. Chim. Acta411(7–8), 546–552 (2010).
   PubMed Web of Science ®Google Scholar
• Eisenhofer G , LendersJW, SiegertGet al. Plasma methoxytyramine: a novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status. Eur. J. Cancer48(11), 1739–1749 (2012).
   PubMed Web of Science ®Google Scholar
• Eisenhofer G , KopinIJ, GoldsteinDS. Catecholamine metabolism: a contemporary view with implications for physiology and medicine. Pharmacol. Rev.56(3), 331–349 (2004).
   PubMed Web of Science ®Google Scholar
• Perry CG , SawkaAM, SinghRet al. The diagnostic efficacy of urinary fractionated metanephrines measured by tandem mass spectrometry in detection of pheochromocytoma. Clin. Endocrinol. (Oxf.)66(5), 703–708 (2007).
   PubMed Web of Science ®Google Scholar
• Petteys BJ , GrahamKS, ParnasMLet al. Performance characteristics of an LC-MS/MS method for the determination of plasma metanephrines. Clin. Chim. Acta413(19–20), 1459–1465 (2012).
   PubMed Web of Science ®Google Scholar
• Eisenhofer G , GoldsteinDS, WaltherMMet al. Biochemical diagnosis of pheochromocytoma: how to distinguish true- from false-positive test results. J. Clin. Endocrinol. Metab.88(6), 2656–2666 (2003).
   PubMed Web of Science ®Google Scholar
• Willemsen JJ , RossHA, LendersJWet al. Stability of urinary fractionated metanephrines and catecholamines during collection, shipment, and storage of samples. Clin. Chem.53(2), 268–272 (2007).
   PubMed Web of Science ®Google Scholar
• Lenders JW , WillemsenJJ, EisenhoferGet al. Is supine rest necessary before blood sampling for plasma metanephrines? Clin. Chem. 53(2), 352–354 (2007).
   PubMed Web of Science ®Google Scholar
• de Jong WH , EisenhoferG, PostWJet al. Dietary influences on plasma and urinary metanephrines: implications for diagnosis of catecholamine-producing tumors. J. Clin. Endocrinol. Metab.94(8), 2841–2849 (2009).
   PubMed Web of Science ®Google Scholar
• Eisenhofer G , LattkeP, HerbergMet al. Reference intervals for plasma free metanephrines with an age adjustment for normetanephrine for optimized laboratory testing of phaeochromocytoma. Ann. Clin. Biochem.50(Pt 1), 62–69 (2013).
   PubMed Web of Science ®Google Scholar
• Ilias I , SahdevA, ReznekRHet al. The optimal imaging of adrenal tumours: a comparison of different methods. Endocr. Relat. Cancer14(3), 587–599 (2007).
   PubMed Web of Science ®Google Scholar
• Sahdev A , SohaibA, MonsonJPet al. CT and MR imaging of unusual locations of extra-adrenal paragangliomas (pheochromocytomas). Eur. Radiol.15(1), 85–92 (2005).
   PubMed Web of Science ®Google Scholar
• Leung K , StammM, RajaAet al. Pheochromocytoma: the range of appearances on ultrasound, CT, MRI, and functional imaging. AJR Am. J. Roentgenol.200(2), 370–378 (2013).
   PubMed Web of Science ®Google Scholar
• Timmers HJ , TaiebD, PacakK. Current and future anatomical and functional imaging approaches to pheochromocytoma and paraganglioma. Horm. Metab. Res.44(5), 367–372 (2012).
   PubMed Web of Science ®Google Scholar
• Wiseman GA , PacakK, O’DorisioMSet al. Usefulness of 123I-MIBG scintigraphy in the evaluation of patients with known or suspected primary or metastatic pheochromocytoma or paraganglioma: results from a prospective multicenter trial. J. Nucl. Med.50(9), 1448–1454 (2009).
   PubMed Web of Science ®Google Scholar
• Fiebrich HB , BrouwersAH, KerstensMNet al. 6-[F-18]Fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to conventional imaging with (123)I-metaiodobenzylguanidine scintigraphy, computer tomography, and magnetic resonance imaging in localizing tumors causing catecholamine excess. J. Clin. Endocrinol. Metab.94(10), 3922–3930 (2009).
   PubMed Web of Science ®Google Scholar
• Gimenez-Roqueplo AP , Caumont-PrimA, HouzardCet al. Imaging work-up for screening of paraganglioma and pheochromocytoma in SDHx mutation carriers: a multicenter prospective study from the PGL. EVA Investigators. J. Clin. Endocrinol. Metab.98(1), E162–E173 (2013).
   PubMed Web of Science ®Google Scholar
• Jimenez C , RohrenE, HabraMAet al. Current and future treatments for malignant pheochromocytoma and sympathetic paraganglioma. Curr. Oncol. Rep.15(4), 356–371 (2013).
   PubMed Web of Science ®Google Scholar
• Taieb D , NeumannH, RubelloDet al. Modern nuclear imaging for paragangliomas: beyond SPECT. J. Nucl. Med.53(2), 264–274 (2012).
   PubMed Web of Science ®Google Scholar
• Timmers HJ , EisenhoferG, CarrasquilloJAet al. Use of 6-[18F]-fluorodopamine positron emission tomography (PET) as first-line investigation for the diagnosis and localization of non-metastatic and metastatic phaeochromocytoma (PHEO). Clin. Endocrinol. (Oxf.)71(1), 11–17 (2009).
   PubMed Web of Science ®Google Scholar
• Timmers HJ , KozupaA, ChenCCet al. Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma. J. Clin. Oncol.25(16), 2262–2269 (2007).
   PubMed Web of Science ®Google Scholar
• Maurice JB , TrokeR, WinZet al. A comparison of the performance of (6)(8)Ga-DOTATATE PET/CT and (1)(2)(3)I-MIBG SPECT in the diagnosis and follow-up of phaeochromocytoma and paraganglioma. Eur. J. Nucl. Med. Mol. Imaging39(8), 1266–1270 (2012).
   PubMed Web of Science ®Google Scholar
• Amar L , BertheratJ, BaudinEet al. Genetic testing in pheochromocytoma or functional paraganglioma. J. Clin. Oncol.23(34), 8812–8818 (2005).
   PubMed Web of Science ®Google Scholar
• Neumann HP , BauschB, McWhinneySRet al. Germ-line mutations in nonsyndromic pheochromocytoma. N. Engl. J. Med.346(19), 1459–1466 (2002).
   PubMed Web of Science ®Google Scholar
• Gimenez-Roqueplo AP , DahiaPL, RobledoM. An update on the genetics of paraganglioma, pheochromocytoma, and associated hereditary syndromes. Horm. Metab. Res.44(5), 328–333 (2012).
   PubMed Web of Science ®Google Scholar
• Pacak K , JochmanovaI, ProdanovTet al. New syndrome of paraganglioma and somatostatinoma associated with polycythemia. J. Clin. Oncol.31(13), 1690–1698 (2013).
   PubMed Web of Science ®Google Scholar
• Lorenzo FR , YangC, Ng Tang FuiMet al. A novel EPAS1/HIF2A germline mutation in a congenital polycythemia with paraganglioma. J. Mol. Med. (Berl.)91(4), 507–512 (2013).
   PubMed Web of Science ®Google Scholar
• Erlic Z , RybickiL, PeczkowskaMet al. Clinical predictors and algorithm for the genetic diagnosis of pheochromocytoma patients. Clin. Cancer Res.15(20), 6378–6385 (2009).
   PubMed Web of Science ®Google Scholar
• Neumann HP , PawluC, PeczkowskaMet al. Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. JAMA292(8), 943–951 (2004).
   PubMed Web of Science ®Google Scholar
• Boedeker CC , HensenEF, NeumannHPet al. Genetics of hereditary head and neck paragangliomas. Head Neck36(6), 907–916 (2014).
   PubMed Web of Science ®Google Scholar
• Crona J , Delgado VerdugoA, MaharjanRet al. Somatic mutations in H-RAS in sporadic pheochromocytoma and paraganglioma identified by exome sequencing. J. Clin. Endocrinol. Metab.98(7), E1266–E1271 (2013).
   PubMed Web of Science ®Google Scholar
• Favier J , BuffetA, Gimenez-RoqueploAP. HIF2A mutations in paraganglioma with polycythemia. N. Engl. J. Med.367(22), 2161–2162 (2012).
   PubMed Web of Science ®Google Scholar
• Zhuang Z , YangC, LorenzoFet al. Somatic HIF2A gain-of-function mutations in paraganglioma with polycythemia. N. Engl. J. Med.367(10), 922–930 (2012).
   PubMed Web of Science ®Google Scholar
• Pacak K . Preoperative management of the pheochromocytoma patient. J. Clin. Endocrinol. Metab.92(11), 4069–4079 (2007).
   PubMed Web of Science ®Google Scholar
• Lentschener C , GaujouxS, TesniereAet al. Point of controversy: perioperative care of patients undergoing pheochromocytoma removal-time for a reappraisal? Eur. J. Endocrinol. 165(3), 365–373 (2011).
   PubMed Web of Science ®Google Scholar
• Lebuffe G , DossehED, TekGet al. The effect of calcium channel blockers on outcome following the surgical treatment of phaeochromocytomas and paragangliomas. Anaesthesia60(5), 439–444 (2005).
   PubMed Web of Science ®Google Scholar
• Steinsapir J , CarrAA, PrisantLMet al. Metyrosine and pheochromocytoma. Arch. Intern. Med.157(8), 901–906 (1997).
   PubMedGoogle Scholar
• Kinney MA , NarrBJ, WarnerMA. Perioperative management of pheochromocytoma. J. Cardiothorac. Vasc. Anesth.16(3), 359–369 (2002).
   PubMed Web of Science ®Google Scholar
• Shen WT , GroganR, VriensMet al. One hundred two patients with pheochromocytoma treated at a single institution since the introduction of laparoscopic adrenalectomy. Arch. Surg.145(9), 893–897 (2010).
   PubMedGoogle Scholar
• Agarwal G , SadacharanD, AggarwalVet al. Surgical management of organ-contained unilateral pheochromocytoma: comparative outcomes of laparoscopic and conventional open surgical procedures in a large single-institution series. Langenbecks Arch. Surg.397(7), 1109–1116 (2012).
   PubMed Web of Science ®Google Scholar
• Walz MK , AlesinaPF, WengerFAet al. Laparoscopic and retroperitoneoscopic treatment of pheochromocytomas and retroperitoneal paragangliomas: results of 161 tumors in 126 patients. World J. Surg.30(5), 899–908 (2006).
   PubMed Web of Science ®Google Scholar
• Gagner M , BretonG, PharandDet al. Is laparoscopic adrenalectomy indicated for pheochromocytomas? Surgery 120(6), 1076–1079 (1996).
   PubMed Web of Science ®Google Scholar
• Goers TA , AbdoM, MoleyJFet al. Outcomes of resection of extra-adrenal pheochromocytomas/paragangliomas in the laparoscopic era: a comparison with adrenal pheochromocytoma. Surg. Endosc.27(2), 428–433 (2013).
   PubMed Web of Science ®Google Scholar
• Benhammou JN , BorisRS, PacakKet al. Functional and oncologic outcomes of partial adrenalectomy for pheochromocytoma in patients with von Hippel–Lindau syndrome after at least 5 years of follow-up. J. Urol.184(5), 1855–1859 (2010).
   PubMed Web of Science ®Google Scholar
• Asari R , ScheubaC, KaczirekKet al. Estimated risk of pheochromocytoma recurrence after adrenal-sparing surgery in patients with multiple endocrine neoplasia type 2A. Arch. Surg.141(12), 1199–1205 (2006).
   PubMedGoogle Scholar
• Grubbs EG , RichTA, NgCet al. Long-term outcomes of surgical treatment for hereditary pheochromocytoma. J. Am. Coll. Surg.216(2), 280–289 (2013).
   PubMed Web of Science ®Google Scholar
• Bausch B , WellnerU, BauschDet al. Long-term prognosis of patients with pediatric pheochromocytoma. Endocr. Relat. Cancer21(1), 17–25 (2014).
   PubMed Web of Science ®Google Scholar
• Timmers HJ , BrouwersFM, HermusARet al. Metastases but not cardiovascular mortality reduces life expectancy following surgical resection of apparently benign pheochromocytoma. Endocr. Relat. Cancer15(4), 1127–1133 (2008).
   PubMed Web of Science ®Google Scholar
• Plouin PF , ChatellierG, FofolIet al. Tumor recurrence and hypertension persistence after successful pheochromocytoma operation. Hypertension29(5), 1133–1139 (1997).
   PubMed Web of Science ®Google Scholar
• Amar L , FassnachtM, Gimenez-RoqueploAPet al. Long-term postoperative follow-up in patients with apparently benign pheochromocytoma and paraganglioma. Horm. Metab. Res.44(5), 385–389 (2012).
   PubMed Web of Science ®Google Scholar
• Tischler AS . Pheochromocytoma and extra-adrenal paraganglioma: updates. Arch. Pathol. Lab. Med.132(8), 1272–1284 (2008).
   PubMed Web of Science ®Google Scholar
• Amar L , BaudinE, BurnichonNet al. Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas. J. Clin. Endocrinol. Metab.92(10), 3822–3828 (2007).
   PubMed Web of Science ®Google Scholar
• Hescot S , LeboulleuxS, AmarLet al. One-year progression-free survival of therapy-naive patients with malignant pheochromocytoma and paraganglioma. J. Clin. Endocrinol. Metab.98(10), 4006–4012 (2013).
   PubMed Web of Science ®Google Scholar
• Huang H , AbrahamJ, HungEet al. Treatment of malignant pheochromocytoma/paraganglioma with cyclophosphamide, vincristine, and dacarbazine: recommendation from a 22-year follow-up of 18 patients. Cancer113(8), 2020–2028 (2008).
   PubMed Web of Science ®Google Scholar
• Lenders JW . Pheochromocytoma and pregnancy: a deceptive connection. Eur. J. Endocrinol.166(2), 143–150 (2012).
   PubMed Web of Science ®Google Scholar
• Biggar MA , LennardTW. Systematic review of phaeochromocytoma in pregnancy. Br. J. Surg.100(2), 182–190 (2013).
   PubMed Web of Science ®Google Scholar
• Oliva R , AngelosP, KaplanEet al. Pheochromocytoma in pregnancy: a case series and review. Hypertension55(3), 600–606 (2010).
   PubMed Web of Science ®Google Scholar
• James MF , CronjeL. Pheochromocytoma crisis: the use of magnesium sulfate. Anesth. Analg.99(3), 680–686 (2004).
   PubMed Web of Science ®Google Scholar